anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
Shake Well Before Using. One to two drops instilled into the conjunctival sac(s) four times daily. During the initial 24 to 48 hours the dosage may be safely increased to two drops every two hours. If no improvement after two weeks, consult physician. Care should be taken not to discontinue therapy prematurely. 

Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation [see PRECAUTIONS] .
H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.
The primary objective of this study is to investigate the efficacy of psychotherapeutic contacts that aim at motivating and supporting surgical patients with psychiatric disorders in participating in subsequent psychosocial treatment options like psycho- and addiction therapy (RCT). The secondary objective is to investigate whether preoperatively assessed psychosocial factors are associated with surgical outcomes (preoperative computer-assisted self assessment).

The Bridging Intervention in Anesthesiology (BRIA) has been designed as a feasible treatment option to reach patients from all surgical fields. Implemented in the preoperative anesthesiological assessment clinic this therapy program comprises two major elements: (1) A computer assisted self assessment of social, lifestyle and psychological factors including a comprehensive battery of psychiatric screening tests; (2) Psychotherapeutic contacts with the objective to motivate patients with psychiatric disorders and support them in participating in subsequent psychosocial treatment programs. The self assessment will be offered to all adult surgical patients of the preoperative anesthesiological assessment clinic during inclusion period (current 5104 patients). Data on surgical outcomes will be collected prospectively during a 6-month-follow-up, and regression analyses will be performed to determine the extent of associations between psychosocial factors and outcomes. Patients with clinically relevant psychological distress (i.e. scoring above the cut-off of one of applied standardized screening questionnaires) will be offered to participate in the RCT on the psychotherapy part of BRIA (220 patients). Data on primary and secondary outcomes will be collected 6 months and 24 months, respectively, after baseline assessment.
Ventricular septal rupture, a formidable complication of acute myocardial infarction (AMI), is linked to significant morbidity and mortality. The clinical manifestation typically involves pronounced hemodynamic compromise necessitating prompt surgical intervention. This report outlines the case of a 60-year-old male presenting with acute heart failure 3 weeks post a presumed AMI. On evaluation, a substantial ventricular septal defect with left-to-right shunt was observed. The patient, although hemodynamically stable with mild symptoms, underwent surgical closure of the defect and coronary artery bypass graft for multivessel coronary artery disease. This case contributes to the literature on the delayed presentation of post-myocardial infarction (MI) ventricular septal rupture, a scenario deviating from the anticipated severe hemodynamic instability given the timing of the MI and the extent of the septal defect.
Carpal tunnel syndrome (CTS) affects over 60 million people worldwide. If a regimen of conservative management has failed, surgical release of the median nerve is warranted. Numerous approaches for carpal tunnel release have been described that range from an open technique to a limited incision to endoscopic release. In addition, partial excision of the flexor retinaculum is advocated by some surgeons because of obtaining better outcomes. However, the procedure is difficult to be accomplished through small incisions owing to poor visualization. Currently, balance of incision, visualization, and partial excision of the flexor retinaculum is still controversial.

The objective of this report is to introduce carpal tunnel release with partial excision of the flexor retinaculum through two small incisions. The procedures were performed under lighted head magnifier. This is the first report on the use of our technique. For comparison, the investigators also included two other groups of standard open carpal tunnel release with partial excision of the flexor retinaculum and endoscopic carpal tunnel release without excision of the flexor retinaculum.
Hypertension is one of the leading causes of death due to target organ injury from cardiovascular disease. Although there are many treatments, only one-sixth of hypertensive patients effectively control their blood pressure. Therefore, further understanding the pathogenesis of hypertension is essential for the treatment of hypertension. Much research shows that immune cells play an important role in the pathogenesis of hypertension. Here, we discuss the roles of different immune cells in hypertension. Many immune cells participate in innate and adaptive immune responses, such as monocytes/macrophages, neutrophils, dendritic cells, NK cells, and B and T lymphocytes. Immune cells infiltrate the blood vessels, kidneys, and hearts and cause damage. The mechanism is that immune cells secrete cytokines such as interleukin, interferon, and tumor necrosis factor, which affect the inflammatory reaction, oxidative stress, and kidney sodium water retention, and finally aggravate or reduce the dysfunction, remodeling, and fibrosis of the blood vessel, kidney, and heart to participate in blood pressure regulation. This article reviews the research progress on immune cells and hypertension.
Fragile X Syndrome (FXS) is an X-linked disorder leading to the loss of expression of FMR1-protein product, FMRP. The absence or deficiency of FMRP is thought to result in the characteristic FXS phenotypes, including intellectual disability. Identifying the relationship between FMRP levels and IQ may be critical to better understand underlying mechanisms and advance treatment development and planning. A sample of 143 individuals with FXS (69% male), aged 8-50 years, completed IQ testing and blood draw via venipuncture to determine the relationship between Deviation IQ scores and FMRP levels as well as the distribution of Deviation IQ scores. In both males and females with FXS, higher FMRP levels were associated with higher Deviation IQ. However, this relationship was no longer significant when only examining full mutation, fully-methylated males. Yet, both the full and restricted male samples showed a downward shifted but otherwise normal distribution of Deviation IQ scores. Our findings support and extend previous studies establishing molecular markers of disease severity in FXS as well as provide novel evidence of a "FXS IQ standard curve". This latter finding suggests inter-individual variation in Deviation IQ in FXS, especially among males, may be driven by similar factors known to impact cognitive outcomes in typically-developing individuals. Thus, future work aimed at understanding the mechanisms by which FMRP loss leads to intellectual disability should revisit the biological/genetic, socio-environmental, and epigenetic factors contributing to inter-individual variation in IQ in FXS.
Cardio-cerebrovascular diseases encompass pathological changes in the heart, brain and vascular system, which pose a great threat to health and well-being worldwide. Moreover, metabolic diseases contribute to and exacerbate the impact of vascular diseases. Inflammation is a complex process that protects against noxious stimuli but is also dysregulated in numerous so-called inflammatory diseases, one of which is atherosclerosis. Inflammation involves multiple organ systems and a complex cascade of molecular and cellular events. Numerous studies have shown that inflammation plays a vital role in cardio-cerebrovascular diseases and metabolic diseases. The absent in melanoma 2 (AIM2) inflammasome detects and is subsequently activated by double-stranded DNA in damaged cells and pathogens. With the assistance of the mature effector molecule caspase-1, the AIM2 inflammasome performs crucial biological functions that underpin its involvement in cardio-cerebrovascular diseases and related metabolic diseases: The production of interleukin-1 beta (IL-1β), interleukin-18 (IL-18) and N-terminal pore-forming Gasdermin D fragment (GSDMD-N) mediates a series of inflammatory responses and programmed cell death (pyroptosis and PANoptosis). Currently, several agents have been reported to inhibit the activity of the AIM2 inflammasome and have the potential to be evaluated for use in clinical settings. In this review, we systemically elucidate the assembly, biological functions, regulation and mechanisms of the AIM2 inflammasome in cardio-cerebrovascular diseases and related metabolic diseases and outline the inhibitory agents of the AIM2 inflammasome as potential therapeutic drugs.
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants will be screened within 28 days prior to the first dose of study intervention to confirm study eligibility. Subjects must have moderate-severe AD involving at least 10% Body Surface Area (BSA); an Investigator Global Assessment (IGA) score of at least 3; an Eczema Area Severity Index (EASI) of at least 16 and Peak Pruritus Numerical Rating Score (NRS) of at least 4 on baseline/Day 1. Eligible subjects will be randomized at the Baseline/Day 1 visit. Approximately 225 participants will be randomized in a 1:1:1 ratio to receive once daily PF 04965842 at 200 mg, 100 mg, or placebo for 12 weeks. Randomization will be stratified by baseline disease severity (moderate \[IGA = 3\] vs. severe \[IGA = 4\] AD). The investigational products will be administered QD for 12 weeks. Background therapy (medicated and non-medicated topical therapy) must be applied BID for the duration of the treatment period. The co-primary efficacy endpoints are an IGA score of clear (0) or almost clear (1) with a reduction from baseline of greater than 2 points at Week 12 AND an at least 75% improvement of the EASI score (EASI-75) at week 12. Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment. Scheduled clinic or telephone study visits for all subjects will occur at Screening, Baseline/Day 1, Day 8 (by phone), Day 15, Day 29, Day 43 (by phone), Day 57, Day 85 (End of treatment/Early termination), Day 113 (End of Study). Participants discontinuing early from the study will undergo a 4 week follow up period.

This study includes an immunogenicity sub study integrated into the last 4 weeks of the main study treatment period. At Week 8, up to approximately 90 participants (up to approximately 30 in each treatment arm) who have completed 8 weeks of treatment with study intervention will receive a tetanus, diphtheria and acellular pertussis combination vaccine (Tdap), and collection of blood samples for the evaluation of immunogenicity at Weeks 8 and 12. Participants of this sub study will complete all other protocol specified procedures in the main study.

At the end of the 12 week study treatment, qualified participants completing the study will have the option to enter the long term extension (LTE) study B7451015.
FIELD: medicine, ophthalmology. SUBSTANCE: invention relates to the composition eliciting antiseptic properties and including an antiseptic agent miramystin, sodium chloride isotonic solution or sodium chloride solution of increased viscosity. Increased viscosity is provided by addition of different modified species of cellulose (preferably, hydroxyethylcellulose) as gel-forming agent. Developed composition has no toxic effect on eye mucosa and body of animals. Composition shows high effectiveness in treatment of experimental suppurative conjunctivitis and provides treatment of infectious lesions of eye. EFFECT: enhanced effectiveness, absence of toxicity. 5 cl, 2 tbl
Patients with oxygen saturation \> 97% will only be observed. ORi values will be recorded blindly from the clinician. Adjustments to be made in FiO2 will be determined by the intensive care doctor independently of the study, and only observation will be made in this group.
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Antiviral therapies are considered to be one of the COVID-19 treatments. Remdesivir and favipiravir are the antivirals recommended by Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism to inhibit virus replication, specifically by inhibiting RNA-dependent RNA polymerase (RdRp) of the virus. Several studies reported that patients who received these antivirals had a lower duration of hospitalization. However, the effectiveness comparison of remdesivir and favipiravir remains unknown.

An observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021 are collected by consecutive sampling technique, and this research was carried out at Gotong Royong Hospital Surabaya.
Linagliptin did not increase the incidence of tumors in male and female rats in a 2-year study at doses of 6, 18, and 60 mg/kg. The highest dose of 60 mg/kg is approximately 418 times the clinical dose of 5 mg/day based on AUC exposure. Linagliptin did not increase the incidence of tumors in mice in a 2-year study at doses up to 80 mg/kg (males) and 25 mg/kg (females), or approximately 35- and 270-times the clinical dose based on AUC exposure. Higher doses of linagliptin in female mice (80 mg/kg) increased the incidence of lymphoma at approximately 215-times the clinical dose based on AUC exposure.

Linagliptin was not mutagenic or clastogenic with or without metabolic activation in the Ames bacterial mutagenicity assay, a chromosomal aberration test in human lymphocytes, and an in vivo micronucleus assay.

In fertility studies in rats, linagliptin had no adverse effects on early embryonic development, mating, fertility, or bearing live young up to the highest dose of 240 mg/kg (approximately 943-times the clinical dose based on AUC exposure).
Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
Patellofemoral pain syndrome is one of the best-known causes of anterior knee joint pain. Proximal and distal joint muscle imbalances are the most prevalent factors in knee pain, especially in the knee cap. Patellofemoral pain syndrome is the most prevalent reason that brings young individuals to sports clinics. Possible mechanism that is used to explain the possibility of the occurrence of PFPS has been identified as joint pain, which in turn causes reflexive inhibition of VMO, Glut max, muscular weakness, reduces knee function, and causes discomfort and pain in the knee joint. Pain is aggravated with repetitive activities such as squatting, descending stairs, running and jumping. Individuals with PFPS may experience a loss of equilibrium and impaired function due to a lack of proprioception. Neuromuscular electrical stimulation, hip abductors and external rotator strengthening with proprioceptive training, and mayofascial release to the gluteal medius are some of the techniques that can be used for the management of PFPS. Athletic performance depends on the number of skills that require balance and muscular control. This particular study focuses on the comparative effects of functional stabilization and perturbation training.

A randomized clinical study will be conducted at pakistan sports board Board in Lahore on athletes with patellofemoral pain syndrome. The sample size of the study was calculated using G.Power. Non -Probability convenient sampling technique will be used for research. The sample size will be 34. The sample will be split into 2 groups. FSE along with traditional treatment, will be given to Group 1 and perturbation training will be given to Group 2. Tools that will be used to assess the baseline measures include (NPRS), horizontal and vertical jump tests, the lower extremity functional scale (LEFS), 40-yard splint tests, and the star excursion balance test before and after the intervention. The data will be analyzed using SPSS version 25. First, the Shapiro-Wilk test will be used to determine the normality of the data; the P-value will be greater than 0.05, and the data will be distributed normally. After assessing the normality of the data, it will be decided whether a parametric or non-parametric test will be used withn and between two groups.
PURPOSE: To enable the constitution of high-contrast and low-noise two-dimensional images from three-dimensional magnetic resonance fluid flow data by subjecting the data to specific statistical processing. CONSTITUTION: Respective entries correspond to the volume elements of the fluid stream or fixed structures or the volume pixel values of the magnetic resonance collected from the volume of a testee. A projection line 48 passes the data volume at a prescribed angle and the three-dimensional data set entries 46 corresponding to all the intersecting volume elements are selected. The average and standard deviation of the entries of the set are determined. After a projection average is subjected from the respective entries, the power equal to the power of the statistic order is determined with respect to the result thereof and the weighted volume element differences are determined. After the sum of the weighted volume element differences is divided by the number of the entries, the result thereof is divided by a normalization constant, by which a projected value is determined.  The procedure is repeated with all the parallel rays intersecting with all the pixels in the projected images, the data set is then displayed as the two-dimensional images.
A purpose of the present invention is to provide an anti-inflammatory agent, a TNF-α production inhibitor, and an IL-10 production promotor which contain a plant-derived active ingredient. Another purpose of the present invention is to provide a food or beverage composition and a skin external application composition which contain a plant-derived active ingredient and which have an anti-inflammatory effect. The anti-inflammatory agent, the TNF-α production inhibitor, and the IL-10 production promotor contain a plant-derived polyamine-containing extract. The plant-derived polyamine-containing extract includes a less-than-1 kDa fraction. The less-than-1 kDa fraction contains an active ingredient. The food or beverage composition and the skin external application composition contain the anti-inflammatory agent.
The most common side effect experienced by people using Transderm Scōp is dryness of the mouth. This occurs in about two thirds of the people. A less frequent side effect is drowsiness, which occurs in less than one sixth of the people. Temporary blurring of vision and dilation (widening) of the pupils may occur, especially if the drug is on your hands and comes in contact with the eyes. On infrequent occasions, disorientation, memory disturbances, dizziness, restlessness, hallucinations, confusion, difficulty urinating, skin rashes or redness, temporary changes in heart rate such as palpitations, dry itchy, or reddened whites of the eyes, and eye pain have been reported. If these effects do occur, remove the patch and call your doctor. Since drowsiness, disorientation, and confusion may occur with the use of scopolamine, be careful driving or operating any dangerous machinery, especially when you first start using the drug system. 

In addition, if you plan to participate in underwater sports while wearing the patch, you should discuss with your doctor the potentially disorienting effects of scopolamine.

Eye Effects: Temporary blurring of vision and dilation (widening) of the pupils may occur, especially if the drug is on your fingers or hands and comes into contact with the eyes. Dry, itchy, or reddened whites of the eye and eye pain have been reported infrequently. In the unlikely event that you experience pain in the eye and reddened whites of the eye, which may be accompanied by widening of the pupil and blurred vision, remove the patch and consult your doctor promptly. Widening of the pupils and blurred vision without pain, or reddened whites of the eye, is usually temporary and not serious.

Drug Withdrawal/Post-Removal Symptoms: Symptoms such as dizziness, nausea, vomiting, headache, and disturbances of equilibrium have been reported by some people following discontinuation of use of the Transderm Scōp patch. These symptoms have occurred most often in people who have used the patches for more than 3 days, and frequently do not appear until 24 hours or more after the patch has been removed. These symptoms may be associated with adaptation from a motion environment to a motion-free environment. It is recommended that you consult with your doctor if these symptoms persist.